Pulling the emergency brake on thrombosis in high-risk PV
Please join us for the Novartis-sponsored webinar entitled ‘Pulling the emergency brake on thrombosis in high-risk PV’. Expert faculty will discuss the unmet needs for patients with PV. This includes patients who remain on hydroxyurea despite a stable suboptimal response, as well as the increased risk of thromboembolic and cardiovascular events in high-risk PV. Using a case-based approach, the faculty will provide their clinical perspective on how to recognize hydroxyurea intolerance/resistance. Finally, they will discuss the latest clinical data on managing high-risk PV and how these insights can be applied to clinical practice.
Learning goals
At the end of the webinar, participants will be able to:
- Review how to recognize treatment failure in high-risk PV in the clinical setting
- Understand the importance of an urgent switch to second-line therapy at the first sign of failure in high-risk PV
- Discuss how the latest clinical data inform treatment decisions that optimize thrombosis-free survival and molecular response in PV
This session is intended for non-US healthcare professionals



